Loading…
← CockpitCompetitor Analysis › SGHT Sight Sciences, Inc.Open in the cockpit ↗

Sight Sciences, Inc.SGHTCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 98
Mkt cap
$599M
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$4.18M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-165.4 pp
WACC 16.5%
Hurdle
n/a
no reverse DCF
Next earnings
112 days
10 Mar 2027
Close · USD$10.77
1D+2.7%
1W-1.4%
1M+24.9%
3M+32.1%
6M+121.6%
YTD+35.8%
1Y+53.2%
ATR %5.1%
Beta1.47
52w lowhigh7.1% off high

What Sight Sciences does

Employees: 186

Sight Sciences at a glance

Size Sight Sciences (SGHT) is a United States Health Care company (Medical Specialties) with a market value of $599M, the 2555th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.77 on 18 Nov 2026.

Performance Over six months the shares gained 121.6%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 16.2% over the last twelve months (peer median +14.4%); the operating margin is -29.5% (peer median 8.5%).

Valuation It trades at 6.4× enterprise value to sales against a peer median of 3.8× (6th most expensive of 20).

Capital Return on invested capital runs 165.4 points below its cost of capital (16.5% WACC).

Short interest Short interest is 2.0% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026SGHT 210Peer median 81
Six months, rebased to 100: Sight Sciences against the median of its 20 peers (local-currency closes).

Sight Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$88.4M$77.4M$79.9M$81.1M$71.3M
Revenue growth—-3%-1%+14%—
Gross profit$77.6M$66.7M$68.3M$69.2M$59.0M
EBITDA-$25.7M-$36.6M-$49.8M-$56.7M-$82.7M
Net income-$28.4M-$38.4M-$51.5M-$55.5M-$86.2M
Free cash flow-$16.9M-$29.9M-$22.7M-$48.0M-$76.9M
Capital expenditure-$9,000$224,000$385,000$791,000$970,000
Total debt$42.1M$40.8M$40.4M$35.4M$35.0M

Quarterly statements and history in the cockpit →

Sight Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%MEDINANTCMD688581300314OBIOXVIVO688236300952PACB47283012356031221789300869QDELSNTSGHT6-month return →1-month return →
Up and to the right = strong over both horizons. Sight Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%5×10×15×MEDINANVVVVTCMD688581300314OBIOXVIVO6882364728603122QDELSGHTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sight Sciences is the large dot.

Sight Sciences competitors and peer comparison

How Sight Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sight Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureSGHTPeer medianRank in peer set
1-month return+24.9%-5.5%2nd highest of 19
6-month return+121.6%-20.3%highest of 19
Distance from 52-week high-7.1%-34.3%4th highest of 20
Revenue growth (TTM)+16.2%+14.4%9th highest of 20
Operating margin-29.5%8.5%4th lowest of 20
EV / Sales6.4×3.8×6th most expensive of 20
ROIC minus cost of capital-165.4 pp+1.7 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sight Sciences SGHTUnited States$599M+122%+16%-30%6.4×n/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%7.1×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%3.8×35.3%+6.7%
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%14.3×n/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%1.5×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%3.7×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%5.4×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%18.3×n/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%6.3×35.9%+35.2%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%2.1×-8.5%+2.2%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%8.3×-2.6%+18.8%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%2.1×-11.5%+6.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
QuidelOrtho QDELUnited States$657M-20%-5%-2%1.4×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
Synektik SNT.WAPoland$662M+10%+32%24%2.9×0.2%+47.5%

Questions

Which companies are Sight Sciences's closest peers?
The cockpit's peer set: Medistim (MEDI.OL), Nanosonics (NAN.AX), Sahajanand Medical Technologies (SMT.NS), vVARDIS (VVVV), Tactile Systems Technology (TCMD), Hangzhou AGS MedTech (688581.SS), Ningbo David Medical Device (300314.SZ), Orchestra BioMed (OBIO).
Is Sight Sciences expensive compared with its peers?
On ev / sales it trades at 6.4× against a peer median of 3.8×, 6th most expensive of 20 in its peer set.
How has Sight Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +121.6% against -20.3% for the median peer; over one year +53.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.